Trehalose

Progranulin (PGRN) is a secreted growth factor important for neuronal survival and may do so, in part, by regulating lysosome homeostasis. Mutations in the PGRN gene (GRN) are a common cause of frontotemporal lobar degeneration (FTLD) and lead to disease ...

Diabetes mellitus is the most prevalent metabolic disorder contributing to significant morbidity and mortality in humans. Many preventative and therap…

HCMV infects multiple cell types in vivo, establishes lifelong persistence in the host, and can cause serious health problems for fetuses and immunocompromised individuals. HCMV, like all other persistent pathogens, has to finely tune its interplay with the host cellular machinery to replicate effic …

Fibrillar accumulation of A53T mutant α-synuclein (A53T-AS) in Lewy bodies is a symptom of Parkinsonism. Inhibitions of the overexpression and fibrillar aggregation of α-synuclein (AS) in vivo could be a promising strategy for treating Parkinson’s disease (PD). In this study, at concentrations lower than 1 mM, trehalose decreased the A53T-AS expression level in transduced PC12 cells. Although H2O2 and aluminum ions increased the expression level and neurotoxicity of A53T-AS in cells, proper trehalose concentrations inhibited the event. These studies adequately prove that trehalose at an appropriate dose would be potentially useful for PD treatment.

Trehalose is a natural disaccharide that is found in a diverse range of organisms but not in mammals. Autophagy is a process which mediates the sequestration, lysosomal delivery and degradation of proteins and organelles. Studies have shown that trehalose exerts beneficial effects through inducing a …

Trehalose (TRE) is a natural, nonreducing disaccharide synthesized by lower organisms. TRE exhibits an extraordinary ability to protect cells against …

Zinc (Zn) deficiency is a clinical consequence of brain injury that can result in neuropathological outcomes that are exacerbated with age. Here, we present laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) imaging data showing modulation of brain Zn levels by the disaccharide trehalose

Epoxy resins are ubiquitous in high-performance composite applications because of their excellent mechanical strength, thermal and chemical resistance, strong adhesion, and low shrinkage after curing. Bio-based epoxy resins derived from natural products such as carbohydrates offer tremendous potential for creating new polymeric materials. Sugars and their derivatives often offer great biodegradability and functionality such as the presence of multiple hydroxyl groups that impart highly cross-linked polymer networks. Moreover, their ring structures can afford polymers with high glass transition temperatures. To develop epoxy resins containing sustainably sourced feedstocks, we designed and synthesized trehalose- and β-cyclodextrin-based carboxylic acid hardeners for epoxy resins and examined the thermal, mechanical, and adhesive properties of the resulting materials. Trehalose and β-cyclodextrin were succinylated with excess succinic anhydride, and the resulting carboxylic acid hardeners formed homogeneous mixtures with trimethylolpropane triglycidyl ether (TTE) in different carboxyl–epoxide ratios. The cured resins were found to be thermally stable (Td5 > 300 °C) and display high Young’s moduli of up to 1.4 and 1.8 GPa with mechanical strengths of 47 and 64 MPa for the trehalose- and β-cyclodextrin-based epoxy resins, respectively. Preliminary adhesion tests showed that the cured resins exhibit excellent lap-shear strengths of 3600 and 2100 psi, respectively. The resins were also degradable into water-soluble components in both aqueous acidic and basic solutions but were relatively stable from hydrolysis in neutral aqueous conditions. These results imply that this novel class of hardeners are promising feedstocks for renewable high performance epoxy resins.

Although vertebrates cannot synthesize the natural disaccharide trehalose, exogenous administration of trehalose to mammalian cells may be beneficial for protein misfolding disorders. In this issue, DeBosch et al . show that trehalose may also be useful in treating nonalcoholic fatty liver disease and identify inhibition of cellular glucose import through SLC2A (also known as GLUT) transporters as a mechanism by which trehalose stimulates autophagy through the adenosine monophosphate–activated protein kinase (AMPK).

Methotrexate (MTX) is commonly used as a standard chemotherapy for many cancers, however its usage required high doses thereby leading to severe adverse effects. In a trial to find a suitable neoadjuvant therapy to decrease MTX dosage without lowering its chemotherapeutic efficacy, we investigated t …

PhD Thesis Abstract Background: Cancer continues to represent the main cause of mortality in the world, the second leading cause of death worldwide next to cardiovascular disease. Therefore, it is important to find effective non-toxic, inexpensive, and suitable neoadjuvant therapy with methotrexate (MTX) to decrease its dosage without lowering its chemotherapeutic efficacy. Aim:  This study aimed to investigate the antitumor effect of trehalose (TRE) on mice bearing Ehrlich ascites carcinoma (EAC) and to test whether it can enhance the anticancer potential of MTX. Materials and Methods: In this experiment, mice were assigned into 8 groups were used for assessment of antitumor activity of TRE. The antitumor activity of TRE was assessed by measuring the survival time, counting tumor cells, monitoring autophagic activity at the cellular level by flow cytometry, monitoring autophagic and apoptotic regulated genes (Caspase 3, Bec1, and Bcl2 genes ) by real-time  PCR, as well as the biochemical parameters, oxidative stress markers in liver homogenate, complete blood picture (CBC) and histological studies of all groups. Results: Treatment of EAC mice with TRE or MTX alone or in combination resulted in a significant decrease in total, viable, and non-viable tumor cells count as well as the tumor volume in comparison with EAC mice. Treatment with TRE alone or in combination MTX induced a significant increase in the hepatic antioxidant status, a significant upregulation in the gene expression of caspase 3, with the highest expression in the combined group, as compared to the non-treated EAC group. On the other hand, the same treatments resulted in a significant downregulation of Bcl2 and Bec1 genes, with the lowest expression in the combined group. These results showed a significant decrease in autophagic activities in both TRE- and TRE+MTX -treated groups as compared to the non-treated EAC group. Histopathological examination revealed normal lobular architecture with central vein and radiating hepatic cell cords in normal control mice. Conclusion: TRE is considered as an autophagic inhibitor for cancer cells which could be used as a potential neoadjuvant for the antitumor drug, MTX, and probably other chemotherapeutic compounds. This new role of TRE coupled with its apoptotic induction property on tumor cells and lack of toxicity on normal cells increases the efficacy of an antitumor drug for treating a spectrum of cancers. (This Ph.D. thesis was approved by the Faculty of Science, Tanta University, Egypt by March 31, 2018).

Trehalose solution was an effective and safe eyedrop for the treatment of moderate to severe dry eye syndrome in this group of patients.

Trehalose is a natural disaccharide synthesized in various life forms, but not found in vertebrates. An increasing body of evidence demonstrates exceptional bioprotective characteristics of trehalose. This review discusses the scientific findings on potential ...

Background The trehalose (Tre) pathway has strong effects on growth and development in plants through regulation of carbon metabolism. Altering either Tre or trehalose 6-phosphate (T6P) can improve growth and productivity of plants as observed under different water availability. As yet, there are no reports of the effects of modification of Tre orT6P on plant performance under limiting nutrition. Results Here we report that nitrogen (N) metabolism is positively affected by exogenous application of Tre in nitrogen-deficient growing conditions. Spraying foliage of tobacco (Nicotiana tabacum) with trehalose partially alleviated symptoms of nitrogen deficiency through upregulation of nitrate and ammonia assimilation and increasing activities of nitrate reductase (NR), glycolate oxidase (GO), glutamine synthetase (GS) and glutamine oxoglutarate aminotransferase (GOGAT) with concomitant changes in ammonium (NH4 +) and nitrate (NO3 −) concentrations, glutamine and amino acids. Chlorophyll and total nitrogen content of leaves and rates of photosynthesis were increased compared to nitrogen-deficient plants without applied Tre. Total plant biomass accumulation was also higher in Tre -fed nitrogen-deficient plants, with a smaller proportion of dry weight partitioned to roots, compared to nitrogen-deficient plants without applied Tre. Consistent with higher nitrogen assimilation and growth, Tre application reduced foliar starch. Minimal effects of Tre feeding were observed on nitrogen-sufficient plants. Conclusions The data show, for the first time, significant stimulatory effects of exogenous Tre on nitrogen metabolism and growth in plants growing under deficient nitrogen. Under such adverse conditions metabolism is regulated for survival rather than productivity. Application of Tre can alter this regulation towards maintenance of productive functions under low nitrogen. This has implications for considering approaches to modifying the Tre pathway for to improve crop nitrogen-use efficiency and production.

This study assessed the therapeutic utility of the autophagy enhancing stable disaccharide trehalose in the Tg2576 transgenic mouse model of Alzheimer's disease (AD) via an oral gavage of a 2% trehalose solution for 31 days. Furthermore, as AD is a neurodegenerative condition in which the transition …

This study assessed the therapeutic utility of the autophagy enhancing stable disaccharide trehalose in the Tg2576 transgenic mouse model of Alzheimer's disease (AD) via an oral gavage of a 2% trehalose solution for 31 days. Furthermore, as AD is a neurodegenerative condition in which the transition …

In this work we investigate the role of CHIP in a new CHIP-mutation related ataxia and the therapeutic potential of trehalose. The patient's fibroblasts with a new form of hereditary ataxia, related to STUB1 gene (CHIP) mutations, and three age and sex-matched controls were treated with epoxomicin a …

Traumatic brain Injury (TBI) is a significant cause of death and long-term disability for which there are currently no effective pharmacological treatment options. In this study then, we utilized a mouse model of TBI to assess the therapeutic potential of the stable disaccharide trehalose, which is …

Objective: To demonstrate the safety and tolerability of repeated high dose IV administration of trehalose (Cabaletta) in OPMD patients, as part of a phase 2 therapy trial. Background: Trehalose is a disaccharide with protein stabilizing and autophagy enhancing properties. It showed efficacy in reducing abnormal protein aggregation in animal models of several human poly A- and poly Q- mediated hereditary neurological disorders (of which OPMD is an example). Design and Methods: Eleven patients with molecularly confirmed OPMD (age: mean 63 years, range 43-78; disease duration: mean 10.6 years, range 1-24) received weekly infusion of 30 gr Cabaletta for 9-16 weeks (at time of abstract submission). Results: No drug-related adverse effects were noted, in particular no cardiovascular changes were observed. A subtle increase (mean= 5 mg[percnt]) in plasma glucose concentrations was observed 1 hour after trehalose administration. No increase in insulin levels was found. Short term glycosuria was recorded, probably due to trehalase activity in the kidney. Levels of plasma trehalose after a single administration in humans reached the expected concentrations determined in the animal studies as necessary for intracellular activity of trehalose (max. levels of 1000-2000 mgr/mL after 1 hour) and were retained up to 5 hours. Conclusions: Based on these preliminary findings, high dose IV trehalose (Cabaletta) is safe in humans. Clinical trials in OPMD and spinocerebellar atrophy type 3 are currently going on. More disorders with similar PolyA/Poly Q genotypic changes may be suitable for such trials. Disclosure: Dr. Argov has received personal compensation for activities with BioBlast Pharma as chief medical officer. Dr. Vornovitsky has nothing to disclose. Dr. Blumen has received personal compensation for activities with Bioblast Pharma as a consultant. Dr. Caraco has received personal compensation for activities with Sanofi, NeuroDerm, and Roche as a consultant. Thursday, April 23 2015, 2:00 pm-6:30 pm

Traumatic brain Injury (TBI) is a significant cause of death and long-term disability for which there are currently no effective pharmacological treatment options. In this study then, we utilized a mouse model of TBI to assess the therapeutic potential of the stable disaccharide trehalose, which is …

Machado-Joseph disease (MJD) is relatively prevalent among the Yemenite Jewish subpopulation living in Israel. Currently, there is no treatment able to modify the disease progression. Trehalose is a disaccharide with protein-stabilizing and autophagy-enhancing properties. In animal models of MJD, trehalose showed reduction of cerebellar lesion size and improved motor function. This study was designed to be a proof-of-concept, phase 2 study lasting 6 to 12 months, to determine the safety, tolerability, and efficacy of weekly IV administration of 15 g or 30 g 10% trehalose solution in 14 MJD patients. Primary endpoints were safety and tolerability, which were assessed by various clinical and laboratory tests. Secondary endpoints were changes in the Scale for Assessment and Rating of Ataxia (SARA) score, Neurological Examination Score for Spinocerebellar Ataxia (NESSCA), time to do 9-hole peg test (9HPT), time to do 8-meter walk (8MW), and quality of life assessed by the World Health Organization Quality-of-Life Questionnaire-BREF (WHOQoL-BREF). Trehalose was well tolerated, and no serious drug-related adverse events were noted. The average SARA score, NESSCA, and time to do 9HPT and 8MW and the WHOQoL-BREF for all patients remained stable at 6 months. Six patients received treatment for as long as 12 months and continued to remain stable on all the above tests. IV trehalose seems to be safe in humans and probably effective to stabilize neurological impairment in MJD.

Trehalose is a non-reducing sugar formed from two glucose units. Trehalose induces abundant autophagy in cultured cells and also reduces the rate of aggregation of the huntingtin protein in the animal model of Huntington disease, a chronic neurological ...

Trehalose, a disaccharide of glucose, is a naturally occurring nontoxic and nonreducing bioactive sugar. Trehalose is synthetized by many organisms when cells are exposed to stressful conditions, including dehydration, heat, oxidation, hypoxia or even anoxia. Although trehalose is not synthesized by …

The results suggest that trehalose may have antidepressant-like properties. It is hypothesized that these behavioral changes could be related to trehalose effects to enhance autophagy.

During an investigation of subvisible particles found in lyophilized formulations of intravenous immunoglobulin, we used resonant mass measurement tec…

Alzheimer's disease is an irreversible and progressive brain disorder featured by the accumulation of Amyloid-β (Aβ) peptide, which forms insoluble assemblies that builds up into plaques resulting in cognitive decline and memory loss. The formation of fibrillar amyloid deposits is accompanied by con …

Our findings demonstrate that trehalose, functioning as an autophagy enhancer, suppresses the inflammatory response by promoting autophagic flux via TFEB activation in primary HCECs exposed to hyperosmotic stress, a process that is beneficial to dry eye.